When Less May Be Enough: Dose Selection Strategies for Immune Checkpoint Inhibitors Focusing on AntiPD-(L)1 Agents
AbstractEarly clinical trials investigating antiPD(L)-1 agents rarely reached a maximum tolerated dose (MTD), and efficacy signals were observed even at the lowest dose levels. Most extended treatment intervals investigated indicated that these drugs do not follow a direct dose-toxicity or dose-efficacy relationship. Within this context and considering the high cost of an tiPD(L)-1 agents, there is a significant debate on whether lower doses or the administration of such agents at an extended interval should be prospectively evaluated in already-approved agents, or at least be considered in novel combination trials inv...
Source: Targeted Oncology - June 10, 2022 Category: Cancer & Oncology Source Type: research
A Phase 2 Trial of Afatinib in Patients with Solid Tumors that Harbor Genomic Aberrations in the HER family: The MOBILITY3 Basket Study
ConclusionsIn the MOBILITY3 study (NCT02506517), afatinib demonstrated modest activity in tumors that possessEGFR andERBB2 aberrations. Clinical benefit seen in all 3 salivary gland cancers supports the growing evidence for the utility of HER-targeted therapies in the treatment of this specific tumor type. (Source: Targeted Oncology)
Source: Targeted Oncology - May 30, 2022 Category: Cancer & Oncology Source Type: research
Antibody –Drug Conjugates in Uro-Oncology
AbstractCurrently available treatment options for patients with refractory metastatic prostate, bladder, or kidney cancers are limited with the prognosis remaining poor. Advances in the pathobiology of tumors has led to the discovery of cancer antigens that may be used as the target for cancer treatment. Antibody –drug conjugates (ADCs) are a relatively new concept in cancer treatment that broaden therapeutic landscape. ADCs are examples of a ‘drug delivery into the tumor’ system composed of an antigen-directed antibody linked to a cytotoxic drug that may release cytotoxic components after binding to t he antigen loc...
Source: Targeted Oncology - May 14, 2022 Category: Cancer & Oncology Source Type: research
Genomic Landscape of Primary Tumor Site and Clinical Outcome for Patients with Metastatic Colorectal Cancer Receiving Standard-of-Care Chemotherapy
ConclusionsPrimary tumor site is a clinically useful biomarker to predict survival in patients with metastatic colorectal cancer treated with first-line chemotherapy. Moreover, the prognostic or predictive value of several gene alterations by primary tumor site should be considered in clinical practice. (Source: Targeted Oncology)
Source: Targeted Oncology - May 7, 2022 Category: Cancer & Oncology Source Type: research
Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
The article “Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer. (Source: Targeted Oncology)
Source: Targeted Oncology - May 5, 2022 Category: Cancer & Oncology Source Type: research
Changes in Real-World Outcomes in Patients with Metastatic Renal Cell Carcinoma from the Molecular-Targeted Therapy Era to the Immune Checkpoint Inhibitor Era
ConclusionsThe present multi-institution real-world data showed the improved outcome of previously untreated patients with metastatic renal cell carcinoma in the ICI era group compared with that in the molecular-targeted therapy era group. These findings strongly encourage the use of ICI-based treatment for patients with metastatic renal cell carcinoma in the real-world setting. Further studies with extended follow-up periods are needed to confirm our findings. (Source: Targeted Oncology)
Source: Targeted Oncology - April 23, 2022 Category: Cancer & Oncology Source Type: research
The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan
ConclusionsOur research demonstrates that there was no strong evidence showing that patients taking osimertinib as first-line treatment experienced longer median progression-free survival and overall survival than patients treated with afatinib. However, there was a statistical significance revealing that osimertinib provided better median progression-free survival than afatinib in patients with brain metastasis at baseline. (Source: Targeted Oncology)
Source: Targeted Oncology - April 23, 2022 Category: Cancer & Oncology Source Type: research
Molecular Pathogenesis of Sporadic Desmoid Tumours and Its Implications for Novel Therapies: A Systematised Narrative Review
AbstractSporadic desmoid-type fibromatosis is a rare, fibroblastic soft-tissue neoplasm with local aggressiveness but no metastatic potential. Aberrant Wnt/ β-catenin signalling has been extensively linked to desmoid pathogenesis, although little is known about other molecular drivers and no established treatment approach exists. We aimed to summarise the current literature regarding the molecular pathogenesis of sporadic desmoid-type fibromatosis and to discuss the effects of both current and emerging novel therapies targeting these mechanisms. A literature search was conducted of MEDLINE® ALL and EMBASE databases for p...
Source: Targeted Oncology - April 21, 2022 Category: Cancer & Oncology Source Type: research
Correction to: MYL-1402O: A Bevacizumab Biosimilar
(Source: Targeted Oncology)
Source: Targeted Oncology - April 18, 2022 Category: Cancer & Oncology Source Type: research
Correction to: A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies
(Source: Targeted Oncology)
Source: Targeted Oncology - April 12, 2022 Category: Cancer & Oncology Source Type: research
Correction to: Phase I Study of Glesatinib (MGCD265) in Combination with Erlotinib or Docetaxel in Patients with Advanced Solid Tumors
(Source: Targeted Oncology)
Source: Targeted Oncology - April 5, 2022 Category: Cancer & Oncology Source Type: research
Clinical Utility of Genomic Profiling Tests in Patients with Advanced Gastrointestinal Cancers
ConclusionsAlthough their genomic profiles revealed fewer druggable sites, patients with GI cancers accessed targeted therapies similarly to patients with non-GI cancers. The utility of genomic profile testing in patients with GI cancers was highlighted to determine if patients can receive specific treatments, such as HER2-targeted and BRAF-targeted therapies. (Source: Targeted Oncology)
Source: Targeted Oncology - April 2, 2022 Category: Cancer & Oncology Source Type: research
Phase I Study of Glesatinib (MGCD265) in Combination with Erlotinib or Docetaxel in Patients with Advanced Solid Tumors
ConclusionsThe safety profile of glesatinib plus erlotinib or docetaxel was acceptable and there were no PK interactions. MADs of glesatinib 700 mg twice daily (micronized V2) with erlotinib 150 mg once daily or docetaxel 75 mg/m2 every 3 weeks exceeded the MTD by a small margin. Modest signals of efficacy were observed with these treatment combinations in non-genetically selected patients with advanced solid tumors.Clinical Trials RegistrationClinicalTrials.gov NCT00975767; 11 September 2009. (Source: Targeted Oncology)
Source: Targeted Oncology - March 28, 2022 Category: Cancer & Oncology Source Type: research
Phase I Study of Glesatinib (MGCD256) in Combination with Erlotinib or Docetaxel in Patients with Advanced Solid Tumors
ConclusionsThe safety profile of glesatinib plus erlotinib or docetaxel was acceptable and there were no PK interactions. MADs of glesatinib 700 mg twice daily (micronized V2) with erlotinib 150 mg once daily or docetaxel 75 mg/m2 every 3 weeks exceeded the MTD by a small margin. Modest signals of efficacy were observed with these treatment combinations in non-genetically selected patients with advanced solid tumors.Clinical Trials RegistrationClinicalTrials.gov NCT00975767; 11 September 2009. (Source: Targeted Oncology)
Source: Targeted Oncology - March 28, 2022 Category: Cancer & Oncology Source Type: research
Impact of Dose Intensity on Pathologic Complete Response Rate in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Docetaxel, Carboplatin, Trastuzumab and Pertuzumab (TCHP)
ConclusionThe TCHP regimen, which combines chemotherapy and HER2-directed therapy is effective at obtaining pCR in patients with locally advanced HER2+ breast cancer. These results suggest that the dose intensity of the individual agents did not have a significant impact on pCR rates. Given these findings, providers may be more comfortable allowing dose reductions for greater patient tolerability without sacrificing efficacy. (Source: Targeted Oncology)
Source: Targeted Oncology - March 24, 2022 Category: Cancer & Oncology Source Type: research
